CSR. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines. WHO
This summary describes the current status of the development of new candidate H5N1 vaccine viruses and is meant to provide guidance for national authorities and vaccine companies on the selection of candidate viruses for use in vaccine development. The selection of H5N1 vaccine viruses should consider the geographical spread, epidemiology, and antigenic and genetic properties of recently circulating H5N1 viruses.
Clinical trials using both clade 1 and clade 2 viruses should continue as an essential element in pandemic preparedness.
Full text - September 2008 [pdf 157kb]Previous summaries
February 2008 [pdf 741kb]March 2007 [pdf 144kb]
August 2006 [pdf 42kb]
See Also:
Latest articles in those days:
- Highly pathogenic avian influenza as a systemic risk - implications for control and preparedness 19 hours ago
- Multiple introductions and spread of novel reassortant highly pathogenic avian influenza A (H5N1) clade 2.3.4.4b viruses via wild birds, South Korea, 2024-2025 19 hours ago
- [preprint]The mammalian-adaptive PB2-E627K substitution preserves viral fitness of clade 2.3.4.4b H5N1 HPAIV in birds 1 days ago
- Mallard super-shedders of avian influenza exhibit distinct cloacal microbial abundance profiles 1 days ago
- A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge 1 days ago
[Go Top] [Close Window]
